{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T20:00:12Z","timestamp":1792699212178,"version":"4.5.0"},"reference-count":32,"publisher":"American Society for Clinical Investigation","issue":"20","license":[{"start":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T00:00:00Z","timestamp":1761091200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000055","name":"National Institute on Deafness and Other Communication Disorders","doi-asserted-by":"crossref","award":["1 ZIA DC000079"],"award-info":[{"award-number":["1 ZIA DC000079"]}],"id":[{"id":"10.13039\/100000055","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10,22]]},"abstract":"<jats:sec>\n                    <jats:title>BACKGROUND<\/jats:title>\n                    <jats:p>\n                      Cisplatin is often the cytotoxic drug of choice for chemoradiation therapy (CRT) for head and neck squamous cell carcinoma (HNSCC), but it can lead to irreversible hearing loss. There may be similar oncologic outcomes but different toxicity profiles depending on whether cisplatin is given at 75\u2013100 mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      every 3 weeks or 30\u201340 mg\/mg\n                      <jats:sup>2<\/jats:sup>\n                      weekly. This study compares cisplatin-induced hearing loss in patients with HNSCC receiving similar cumulative doses of cisplatin administered either on higher-dose or lower-dose treatment schedules.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS<\/jats:title>\n                    <jats:p>\n                      Using the Enhancing Cancer Hearing Outcomes (ECHO) dataset from 5 academic centers, we conducted a multicenter retrospective cohort study of adults (\u226518 years) with HNSCC receiving cisplatin-based CRT. Participants were grouped by cisplatin dose schedule: every 3 weeks (\u226575 mg\/m\u00b2) or weekly (&lt;75 mg\/m\u00b2). Hearing loss was assessed using American Speech-Language-Hearing Association (ASHA) and Common Terminology Criteria for Adverse Events (CTCAE) v5.0 threshold shift criteria based on audiograms obtained \u2264120 days before and after treatment. Risk differences and predictors of hearing loss were evaluated using \u03c7\n                      <jats:sup>2<\/jats:sup>\n                      analyses and multivariate regression. Kaplan-Meier curves assessed overall and disease-free survival.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>Among 564 participants (1,127 ears), lower-dose weekly cisplatin was associated with significantly lower incidence of hearing loss (ASHA criteria: 57% vs. 82%; CTCAE criteria: 39% vs. 69%). CTCAE grade \u22652 hearing loss occurred in 18% of the weekly group versus 50% of the 3-week group. Multivariate analysis confirmed treatment schedule as an independent predictor of ototoxicity. Two-year survival outcomes did not differ between groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS<\/jats:title>\n                    <jats:p>Weekly low-dose cisplatin significantly reduced the incidence and severity of hearing loss without compromising survival, supporting its broader use in CRT for HNSCC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1172\/jci.insight.196230","type":"journal-article","created":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T18:00:42Z","timestamp":1761069642000},"source":"Crossref","is-referenced-by-count":6,"title":["Lower, more frequent cisplatin dosing minimizes hearing loss in head and neck cancer"],"prefix":"10.1172","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0522-388X","authenticated-orcid":true,"given":"Katharine A.","family":"Fernandez","sequence":"first","affiliation":[{"name":"National Institute on Deafness and Other Communication Disorders, Bethesda, Maryland, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abu S.","family":"Chowdhury","sequence":"additional","affiliation":[{"name":"National Institute on Deafness and Other Communication Disorders, Bethesda, Maryland, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Bonczkowski","sequence":"additional","affiliation":[{"name":"National Institute on Deafness and Other Communication Disorders, Bethesda, Maryland, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4924-4730","authenticated-orcid":true,"given":"Paul D.","family":"Allen","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology, University of Rochester Medical Center, Rochester, New York, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maura H.","family":"Campbell","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology, University of Rochester Medical Center, Rochester, New York, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David S.","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology \u2014 Head and Neck Surgery, Washington University in St. Louis, St. Louis, Missouri, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charvi","family":"Malhotra","sequence":"additional","affiliation":[{"name":"Stanford University, Division of Oncology, Stanford, California, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8663-8141","authenticated-orcid":true,"given":"Brandi R.","family":"Page","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology and Molecular Sciences, Johns Hopkins University, Baltimore, Maryland, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah A.","family":"Mulford","sequence":"additional","affiliation":[{"name":"Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, New York, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Candice Evita","family":"Ortiz","sequence":"additional","affiliation":[{"name":"Capital Institute of Hearing and Balance, Silver Spring, Maryland, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter L.","family":"Santa Maria","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Kullar","sequence":"additional","affiliation":[{"name":"Manchester Foundation Trust, Manchester, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saad A.","family":"Khan","sequence":"additional","affiliation":[{"name":"Stanford University, Division of Oncology, Stanford, California, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shawn D.","family":"Newlands","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology, University of Rochester Medical Center, Rochester, New York, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole C.","family":"Schmitt","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology \u2014 Head and Neck Surgery, Emory University, Atlanta, Georgia, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa L.","family":"Cunningham","sequence":"additional","affiliation":[{"name":"National Institute on Deafness and Other Communication Disorders, Bethesda, Maryland, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"232","published-online":{"date-parts":[[2025,10,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2014.07.025"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.2147\/JEP.S267383"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1055\/s-0039-1684048"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.heares.2006.09.015"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.62.0963"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.39.1110"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1200\/OP.22.00710"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.4103\/0973-1482.27584"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30625-8"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2011.10.005"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2014.01.001"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1080\/02841860701846160"},{"issue":"5","key":"B13","first-page":"1185","article-title":"Weekly cisplatin versus standard three-weekly cisplatin in concurrent chemoradiotherapy of head and neck cancer: the Baskent University experience","volume":"12","author":"Kose","year":"2011","journal-title":"Asian Pac J Cancer Prev"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1186\/1748-717X-7-215"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01293"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.29779"},{"key":"B17"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.e12594"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2009.04.014"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2008.06.003"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16122228"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.28672"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2003.08.009"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2024.07.2315"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2021.103345"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djy133"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.673080"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-024-12615-w"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2016.06.004"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoto.2019.3550"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2024.1233"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1172\/JCI142616"}],"container-title":["JCI Insight"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/insight.jci.org\/articles\/view\/196230\/files\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,17]],"date-time":"2026-05-17T15:00:51Z","timestamp":1779030051000},"score":1,"resource":{"primary":{"URL":"https:\/\/insight.jci.org\/articles\/view\/196230"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,22]]},"references-count":32,"journal-issue":{"issue":"20","published-online":{"date-parts":[[2025,10,22]]},"published-print":{"date-parts":[[2025,10,22]]}},"alternative-id":["10.1172\/jci.insight.196230"],"URL":"https:\/\/doi.org\/10.1172\/jci.insight.196230","relation":{},"ISSN":["2379-3708"],"issn-type":[{"value":"2379-3708","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,22]]},"article-number":"e196230"}}